BenzingaDoubao · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 20:32:06·⟳ 抓取 20:32:15 +9s·⚡ 决策 10-19 20:35:30 +3m15s·8.0 天前
CME集团三季报10月21日盘前发布，Benzinga汇总分析师目标价调整（多为10月上旬旧调整）
这是Benzinga的财报前瞻/分析师评级汇总稿，核心数据（一致预期、10月8日国际ADV、10月5-9日目标价调整）此前均已公开并被消化，无新增公司事实或超预期信息；财报本身10月21日才发布，提前两天方向不可判，不构成可交易事件。
📄 原文Benzinga↗ 原文
CME Group Inc. (NASDAQ:CME) will release its third-quarter earnings report before the opening bell on Wednesday, Oct. 2…
不做 CME Group（芝商所）（CME.US）
财报前瞻聚合稿，无新增事实，一致预期与目标价调整均已公开并price-in；实际财报10月21日盘前才发布，方向取决于surprise，提前两天下注无信息优势，回避。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
稿件仅复述CME将于10月21日盘前发财报及一致预期，并罗列10月上旬已公开的分析师目标价上调，无新增利好或利空。真正的价格催化是两天后的实际财报，当前没有可据以做多/做空的增量edge，回避。
🔎 新鲜度:最早出现 2026-10-19 · 扩散 medium · price-in 风险 high ↗
关键理由
- 无：文章不含相对市场预期的新增信息，分析师目标价调整多为10月5-9日的旧动作且评级分歧（德银8月已降至Hold）。
主要风险
- 若按此前瞻提前做多，实际财报的成交量、费率或指引若不及一致预期（EPS 2.98美元/营收17.1亿美元）将直接亏损，属于无信息优势的事件前赌博。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-08-19 · 影响 weakens
德银已于8月19日将CME从Buy下调至Hold（目标价270美元），且巴克莱、瑞银均仅给中性评级，分析师并非一致看多，前瞻不构成单边做多依据。
检索:CME Group Q3 2026 analyst downgrade risks rate volatility revenue 原文 ↗
先例如何影响了这次决策
对本次决策的影响:未据前瞻产生任何头寸；待实际财报surprise明确后再单独研判。
方向:无可对照先例；本文为财报前瞻而非事件本身，不适用历史事件研究。
涨幅量级:不足以校准幅度，真正的财报日反应需待10月21日实际数据。
形态:不适用
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 13 ms
{"result": "search_processed_events:agent query=`cme group q3 2026 earnings preview analyst price target revisions | cme international adv 22% 9 million contracts q3 | cme 三季度财报前瞻 分析师上调目标价 10月21日`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；
原文全文
展开原文 · 1,965 字
CME Group Inc. (NASDAQ:CME) will release its third-quarter earnings report before the opening bell on Wednesday, Oct. 21.
Analysts expect the Chicago, Illinois-based company to report quarterly earnings of $2.98 per share, up from $2.68 per share in the year-ago period. The consensus estimate for CME’s quarterly revenue is $1.71 billion. It reported $1.54 billion last year, according to Benzinga Pro.
On Oct. 8, CME Group reported that international average daily volume surged 22% to 9 million contracts in the third quarter.
CME Group shares gained 1.5% to close at $293.87 on Friday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.
- Morgan Stanley analyst Michael Cyprys maintained an Overweight rating and raised the price target from $330 to $337 on Oct. 9, 2026. This analyst has an accuracy rate of 67%.
- Barclays analyst Benjamin Budish maintained an Equal-Weight rating and increased the price target from $270 to $281 on Oct. 7, 2026. This analyst has an accuracy rate of 70%.
- UBS analyst Alex Kramm maintained a Neutral rating and boosted the price target from $260 to $270 on Oct. 5, 2026. This analyst has an accuracy rate of 69%.
- TD Cowen analyst Bill Katz maintained a Buy rating and raised the price target from $292 to $300 on Oct. 5, 2026. This analyst has an accuracy rate of 62%.
- Deutsche Bank analyst Brian Bedell downgraded the stock from Buy to Hold and cut the price target from $286 to $270 on Aug. 19, 2026. This analyst has an accuracy rate of 73%.
Considering buying CME stock? Here’s what analysts think:
Photo via Shutterstock
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
Analysts expect the Chicago, Illinois-based company to report quarterly earnings of $2.98 per share, up from $2.68 per share in the year-ago period. The consensus estimate for CME’s quarterly revenue is $1.71 billion. It reported $1.54 billion last year, according to Benzinga Pro.
On Oct. 8, CME Group reported that international average daily volume surged 22% to 9 million contracts in the third quarter.
CME Group shares gained 1.5% to close at $293.87 on Friday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.
- Morgan Stanley analyst Michael Cyprys maintained an Overweight rating and raised the price target from $330 to $337 on Oct. 9, 2026. This analyst has an accuracy rate of 67%.
- Barclays analyst Benjamin Budish maintained an Equal-Weight rating and increased the price target from $270 to $281 on Oct. 7, 2026. This analyst has an accuracy rate of 70%.
- UBS analyst Alex Kramm maintained a Neutral rating and boosted the price target from $260 to $270 on Oct. 5, 2026. This analyst has an accuracy rate of 69%.
- TD Cowen analyst Bill Katz maintained a Buy rating and raised the price target from $292 to $300 on Oct. 5, 2026. This analyst has an accuracy rate of 62%.
- Deutsche Bank analyst Brian Bedell downgraded the stock from Buy to Hold and cut the price target from $286 to $270 on Aug. 19, 2026. This analyst has an accuracy rate of 73%.
Considering buying CME stock? Here’s what analysts think:
Photo via Shutterstock
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
ccab2f5232· 2026-10-19 20:35 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前